Marex Group’s Propanc Biopharma PPCB Stock Holding History

Marex Group’s Portfolio PPCB Stock Details PPCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,709	Closed	-$7.18K	–	1382
2026 Q1	$7.18K	Buy	2,709 +108	+4%	+$641	﹤0.01%	997
2025 Q4	$35.1K	Sell	2,601 -216	-8%	-$5.98K	﹤0.01%	937
2025 Q3	$120K	Buy	+2,817	New	+$182K	﹤0.01%	768

Other funds holding PPCB

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Marex Group's PPCB Position: Q2 2026 in Review

Marex Group sold out of Propanc Biopharma (PPCB) in Q2 2026, closing a stake of 2,709 shares — an estimated $7.18K sold.

Marex Group first reported a position in PPCB in Q3 2025 and held it in 3 quarters. The position peaked at $120K in Q3 2025. 4 funds tracked by Wall St. Rank hold PPCB as of Q2 2026.

Marex Group reported no remaining Propanc Biopharma position as of Q2 2026 after selling out during the quarter.
Marex Group sold 2,709 Propanc Biopharma shares in Q2 2026, an estimated $7.18K.
Marex Group first reported a position in Propanc Biopharma in Q3 2025 and held it in 3 quarters.
Marex Group's Propanc Biopharma position peaked at $120K in Q3 2025.
4 funds tracked by Wall St. Rank held Propanc Biopharma as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.